F-Prime Capital

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

Bluebird Kids Health is a pediatric healthcare provider that aims to build a healthier future for children. It offers a value-based care model, delivering comprehensive, evidence-based care tailored to each family's needs. Services include nutrition support, sleep training, treatments for common ailments like rashes and viruses, all aimed at reducing medical costs and providing personalized care. The company is also developing a proprietary technology platform, enhanced by AI, to proactively manage and coordinate treatment, further simplifying the experience for its clinical team.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Based on our deep science and focused on patients in need.

Shift Bioscience is a biotechnology company focused on combating the diseases associated with aging through innovative cellular reprogramming techniques. The company has developed a high-throughput, high-accuracy aging biomarker, which is integrated into AI-driven simulations to identify safer gene factors for rejuvenation. By leveraging deep learning technology, Shift tests extensive gene combinations to discover potential drug candidates that can reverse aging and age-related diseases. The company's goal is to create a single family of drugs capable of addressing multiple age-related conditions, ultimately allowing for improved health and longevity through simple prescriptions.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of treatment options, including both oral and injectable therapies, specifically targeting incretin, non-incretin, and combination approaches. By integrating proprietary health technology tools, Metsera aims to provide personalized care that meets the evolving demands of weight loss treatment. Its commitment to addressing multiple therapeutic targets positions the company to significantly impact the future of obesity management and related metabolic diseases.

Engrail Therapeutics, Inc. is dedicated to developing and commercializing neuro drugs aimed at treating diseases of the nervous system. Founded in 2019 and based in San Diego, California, the company focuses on creating transformative medicines to alleviate the significant burden of such conditions. One of its key products is ENX-101, a preclinical compound designed to modulate a receptor for GABA, a critical neurotransmitter in the brain. Engrail Therapeutics combines biological insights with clinically meaningful solutions to advance its portfolio of therapies, utilizing a flexible transaction model to efficiently progress its drug candidates from development to commercialization.

HiLabs is a developer of a healthcare data mining platform that aims to enhance data-driven decision-making within healthcare organizations. By leveraging artificial intelligence, HiLabs empowers employees to explore their data intuitively, uncover novel insights, and interact with data visualizations. The platform allows users to customize dashboards and generate new attributes, thus enhancing their ability to understand and utilize client health data effectively. HiLabs recognizes that healthcare providers possess vital domain knowledge but often lack the necessary tools to extract meaningful insights from their data. Through its innovative solutions, HiLabs bridges this gap, enabling healthcare organizations to harness their data more efficiently and improve overall decision-making processes.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

OnCusp Therapeutics is a biopharmaceutical company dedicated to transforming advanced research into innovative cancer treatments. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company focuses on accelerating the development of oncology medications to provide help and hope to cancer patients globally. OnCusp Therapeutics specializes in translating preclinical drug candidates into clinical proof-of-concept stages, aiming to swiftly advance these assets into early global clinical development.

PlasmaGen Biosciences Pvt. Ltd., established in 2010 and based in Bengaluru, India, is a biopharmaceutical company specializing in plasma protein therapies. The company manufactures a range of products including PlasmaGlob and AlbuMax, brands of Normal Human Immunoglobulin for Intravenous use, PlasmaRho-D I.V. for Rh immunization suppression, PlasmaRAB for rabies infection prophylaxis, PlasmaHep for hepatitis B exposure, VerBumin for conditions like hypovolemic shock and burns, and Gammafact-VIII. These products cater to various medical fields such as hematology, oncology, immunology, pediatrics, rheumatology, dermatology, and neurology. The company serves clinicians, medical practitioners, corporate hospitals, and government institutions.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

ARTBIO is a clinical-stage biotechnology company focused on developing innovative radiopharmaceuticals for cancer treatment. The company specializes in radioligand therapy, which utilizes alpha and beta emitters to target and disrupt the DNA of cancer cells. By creating a new class of alpha radioligand therapeutics, ARTBIO aims to enhance the effectiveness of cancer care and provide medical practitioners with novel therapeutic options. In addition to its drug development efforts, ARTBIO is dedicated to building a supportive ecosystem that maximizes the potential of its therapies, ultimately advancing the field of oncology.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree connects pharmaceutical and healthcare brands with healthcare professionals (HCPs) through targeted advertising and data-driven solutions. The platform leverages artificial intelligence, data segmentation, and analytics to accurately identify and engage HCPs across various digital platforms, including physician networking sites and medical journals. By providing access to physician-only platforms, Doceree enables media agencies, pharmaceutical companies, medical device manufacturers, consumer healthcare brands, and hospitals to deliver compliant and effective messaging at scale.

Nvelop Therapeutics is a biotechnology company dedicated to developing advanced genetic medicines aimed at treating severe genetic diseases. The company specializes in creating innovative, programmable delivery systems that facilitate efficient in vivo gene editing and the delivery of therapeutic cargo. By integrating epigenetic editing technologies with next-generation delivery methods, Nvelop Therapeutics addresses significant unmet medical needs. Its focus is on delivering a range of therapeutic payloads, initially prioritizing gene editing within therapeutically relevant cells and tissues, thereby enhancing the potential for effective treatment options for patients suffering from serious genetic conditions.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

K36 Therapeutics is a biotechnology company focused on developing small molecule therapeutics for cancer treatment. The company specializes in translating epigenetic modulation of oncogenic pathways into effective therapies. By leveraging advanced technology, K36 Therapeutics creates orally bioavailable small molecules and selective inhibitors, aiming to enhance the treatment options available to healthcare professionals and improve outcomes for cancer patients.

ARTBIO is a clinical-stage biotechnology company focused on developing innovative radiopharmaceuticals for cancer treatment. The company specializes in radioligand therapy, which utilizes alpha and beta emitters to target and disrupt the DNA of cancer cells. By creating a new class of alpha radioligand therapeutics, ARTBIO aims to enhance the effectiveness of cancer care and provide medical practitioners with novel therapeutic options. In addition to its drug development efforts, ARTBIO is dedicated to building a supportive ecosystem that maximizes the potential of its therapies, ultimately advancing the field of oncology.

Adcentrx Therapeutics is a biotechnology company dedicated to advancing protein conjugate therapeutics aimed at treating cancer and other life-threatening diseases. The company focuses on developing next-generation targeted therapies that leverage the precision of biologics combined with the efficacy of small molecule payloads. Through its innovative approach, Adcentrx aims to enhance treatment options for patients, providing them with more effective and targeted therapeutic solutions.

1upHealth, Inc. is a health data aggregation and centralization company based in Boston, Massachusetts, founded in 2017. It operates a platform that enables patients, providers, and software developers to securely aggregate and share medical data from various electronic medical record systems. The platform consolidates health data into a digital health record that users can control and share with healthcare providers. It facilitates real-time access to updated patient information across multiple health systems, enhancing the ability of providers to deliver informed care. Additionally, the platform automates secure data sharing from electronic medical records and wearable device metrics, allowing for improved healthcare outcomes through a trusted interoperability network.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, founded in 2016. It specializes in providing primary health care services through an artificial intelligence-based platform that connects patients with healthcare professionals. The company focuses on a virtual-first primary care approach, allowing users to access live video appointments with primary care physicians and care teams. This model emphasizes convenience and accessibility without membership fees, enabling patients to make informed decisions about their health. Firefly Health aims to redefine patient care by blending advanced technology with a dedicated care team to ensure continuous and proactive support for common health conditions, including back pain, stomach flu, and women's health issues.

RIGImmune is a biopharmaceutical company dedicated to developing innovative immune-modulating therapies targeting RNA virus diseases and enhancing antitumor immune responses. The company focuses on creating novel treatments aimed at addressing a wide range of conditions associated with viral infections and certain cancers. Its therapeutic candidates are designed to improve treatment outcomes for viral respiratory infections, serving as adjuvants or boosters for healthcare providers. By advancing its research and development efforts, RIGImmune aims to contribute significantly to the treatment landscape for both viral and oncological diseases.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Proximie Inc., headquartered in Bedford, Massachusetts, operates a health technology platform that facilitates remote, real-time collaboration among surgeons worldwide. The company's core service enables surgeons to virtually attend operations via augmented reality, artificial intelligence, and machine learning technologies. This allows them to visually guide complex surgeries, demonstrate techniques, and provide expertise remotely, thereby democratizing access to advanced surgical knowledge globally. Founded by Nadine Hachach-Haram in 2016, Proximie aims to enhance surgical outcomes and improve patient care through innovative telehealth solutions.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree connects pharmaceutical and healthcare brands with healthcare professionals (HCPs) through targeted advertising and data-driven solutions. The platform leverages artificial intelligence, data segmentation, and analytics to accurately identify and engage HCPs across various digital platforms, including physician networking sites and medical journals. By providing access to physician-only platforms, Doceree enables media agencies, pharmaceutical companies, medical device manufacturers, consumer healthcare brands, and hospitals to deliver compliant and effective messaging at scale.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.

K36 Therapeutics is a biotechnology company focused on developing small molecule therapeutics for cancer treatment. The company specializes in translating epigenetic modulation of oncogenic pathways into effective therapies. By leveraging advanced technology, K36 Therapeutics creates orally bioavailable small molecules and selective inhibitors, aiming to enhance the treatment options available to healthcare professionals and improve outcomes for cancer patients.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

AppliedVR, Inc. is a Los Angeles-based company that specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, particularly for pain and anxiety management in settings such as hospitals and surgery centers. Founded in 2013, AppliedVR has established strategic partnerships with institutions like Cedars-Sinai and Children's Hospital Los Angeles. The company's flagship product, EaseVRx, is a pioneering VR-based prescription therapeutic that has received Breakthrough Device Designation from the FDA. This innovative treatment leverages principles of cognitive behavioral therapy and mindfulness to help patients manage chronic pain by changing their pain perception and fostering new coping skills. EaseVRx allows patients to self-administer therapy at home, facilitating remote care and improving access to effective pain management solutions. Through its clinically validated and comprehensive approach, AppliedVR seeks to address the complexities of chronic pain and enhance overall quality of life for patients.

Notable is an AI-driven platform designed to enhance healthcare operations by automating various workflows. With deployment at over 10,000 care sites, Notable automates more than a million repetitive tasks daily, including Registration and Intake, Scheduling and Referrals, and Authorizations. The platform features a voice-powered application that streamlines physician-patient interactions by structuring conversations, dictations, and orders, while also securely recommending billing codes. This automation not only facilitates personalized and efficient patient care but also alleviates the manual workload for healthcare providers, contributing to their financial health.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Orient Speech Therapy Center specializes in providing professional speech and language therapy services for children facing communication challenges, including those with autism or speech disorders. The center focuses on the early screening, clinical diagnosis, and therapeutic interventions essential for improving children's speech and social skills. It offers a range of refined curricula designed specifically for young learners, including the Star Curriculum, phonics and oral muscle courses, expression courses, and exercise classes. Through these structured programs, Orient Speech Therapy Center aims to enhance the communicative abilities of children, enabling them to express themselves more effectively and engage socially.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Protenus, Inc. is a healthcare compliance analytics company based in Baltimore, Maryland, which was founded in 2014. The company specializes in an AI-driven platform designed to audit access to patient records across health systems in the United States. Protenus' technology identifies risks such as inappropriate access to patient data and the misuse of controlled substances by healthcare staff. By automating the detection of policy violations and other anomalous behaviors, the platform supports healthcare organizations in protecting patient privacy and reducing operational risks. Protenus is recognized for its innovation and commitment to fostering safe patient outcomes while enhancing the reputation of healthcare providers. The company has received accolades such as being named one of America's Best Startup Employers by Forbes and recognized as a Great Place to Work.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Proximie Inc., headquartered in Bedford, Massachusetts, operates a health technology platform that facilitates remote, real-time collaboration among surgeons worldwide. The company's core service enables surgeons to virtually attend operations via augmented reality, artificial intelligence, and machine learning technologies. This allows them to visually guide complex surgeries, demonstrate techniques, and provide expertise remotely, thereby democratizing access to advanced surgical knowledge globally. Founded by Nadine Hachach-Haram in 2016, Proximie aims to enhance surgical outcomes and improve patient care through innovative telehealth solutions.

1upHealth, Inc. is a health data aggregation and centralization company based in Boston, Massachusetts, founded in 2017. It operates a platform that enables patients, providers, and software developers to securely aggregate and share medical data from various electronic medical record systems. The platform consolidates health data into a digital health record that users can control and share with healthcare providers. It facilitates real-time access to updated patient information across multiple health systems, enhancing the ability of providers to deliver informed care. Additionally, the platform automates secure data sharing from electronic medical records and wearable device metrics, allowing for improved healthcare outcomes through a trusted interoperability network.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, founded in 2016. It specializes in providing primary health care services through an artificial intelligence-based platform that connects patients with healthcare professionals. The company focuses on a virtual-first primary care approach, allowing users to access live video appointments with primary care physicians and care teams. This model emphasizes convenience and accessibility without membership fees, enabling patients to make informed decisions about their health. Firefly Health aims to redefine patient care by blending advanced technology with a dedicated care team to ensure continuous and proactive support for common health conditions, including back pain, stomach flu, and women's health issues.

AppliedVR, Inc. is a Los Angeles-based company that specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, particularly for pain and anxiety management in settings such as hospitals and surgery centers. Founded in 2013, AppliedVR has established strategic partnerships with institutions like Cedars-Sinai and Children's Hospital Los Angeles. The company's flagship product, EaseVRx, is a pioneering VR-based prescription therapeutic that has received Breakthrough Device Designation from the FDA. This innovative treatment leverages principles of cognitive behavioral therapy and mindfulness to help patients manage chronic pain by changing their pain perception and fostering new coping skills. EaseVRx allows patients to self-administer therapy at home, facilitating remote care and improving access to effective pain management solutions. Through its clinically validated and comprehensive approach, AppliedVR seeks to address the complexities of chronic pain and enhance overall quality of life for patients.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

Cohort, Inc. is a software company focused on enhancing chronic care management and clinical trial processes. Based in New York with an additional office in San Francisco, the company utilizes clinical artificial intelligence and natural language processing to analyze electronic health records. This analysis includes evaluating diagnostics, medications, and clinical notes to provide context relevant to specific patients and their conditions. Cohort’s software streamlines the identification and enrollment of eligible patients, generates tailored care plans, and automates compliance and billing tasks. The company’s solutions are designed to enable Primary Care Providers to improve the scale, efficiency, and outcomes of their Chronic Care Management programs while facilitating clinical trial identification and enrollment.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

J-Pharma is a pharmaceutical company dedicated to improving human health by developing novel drugs based on a human-genomic approach. The company focuses on creating selective agents to treat specific diseases, with an emphasis on cell membrane transporters closely associated with various illnesses. J-Pharma's intellectual property includes the discovery of important drug transporters within the human body, which can be used to evaluate and optimize the pharmacokinetics of new drug candidates. Their pipeline aims to produce new therapeutic agents and diagnostic methods, particularly targeting cancer treatment through drugs like anti-cancer agents and PET diagnostic agents against LAT1. The company's ultimate goal is to enhance the quality of life for an aging population in industrialized countries and contribute globally to human welfare.

Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to discovering and developing targeted therapies for rare disorders, particularly focusing on neurofibromatosis type 1 and related conditions. The company specializes in addressing diseases driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, including cutaneous neurofibromas and other conditions such as immunosuppressant-mediated squamous cell carcinoma and congenital birthmarks. NFlection Therapeutics is known for its innovative approach to drug formulation, offering treatments in a cosmetically elegant gel that can be applied topically, allowing for localized suppression of the Ras pathway while minimizing systemic side effects associated with oral medications. Established in 2014, the company is headquartered in Wayne, Pennsylvania.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

Owkin, Inc. is an artificial intelligence company that specializes in developing software aimed at improving treatment outcomes for patients, particularly in oncology. Established in 2016, with headquarters in New York and an office in Paris, Owkin employs AI tools to enhance drug discovery and accelerate clinical trials while safeguarding patient privacy through federated learning. The company offers several products, including Owkin Lab for therapeutic data connection, Owkin Loop for validated and packaged models, and a comprehensive software stack. Owkin's portfolio includes 30 live models, with an additional 40 in development, focusing on identifying new drug candidates and elucidating the mechanisms behind treatment efficacy. Co-founded by Thomas Clozel, a clinical research doctor, and Gilles Wainrib, a machine learning expert, Owkin has raised over $255 million and achieved unicorn status due to its innovative approach in addressing unmet medical needs and optimizing the drug development process.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for idiopathic pulmonary fibrosis (IPF) and other serious respiratory conditions. Headquartered in Seattle, Washington, with an additional office in San Diego, the company specializes in an inhaled formulation of pirfenidone, known as AP01. This formulation aims to enhance the amount of medication that reaches the lungs while minimizing side effects associated with oral treatments. Established in 2011, Avalyn Pharma is dedicated to improving care and outcomes for patients with severe respiratory diseases through its advanced therapeutic pipeline and novel inhaled therapeutics. Initially named Genoa Pharmaceuticals, the company rebranded to its current name in July 2017.

Rallybio, LLC is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, focused on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, Rallybio is dedicated to addressing critical medical needs, particularly in the fields of hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. Its lead product candidate, RLYB211, is designed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. The company emphasizes the use of antibodies, small molecules, and engineered proteins in its drug development efforts. Rallybio is supported by a team of experienced professionals with extensive expertise in biopharmaceutical research and development, particularly in the realm of rare diseases.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

WelbeHealth is a healthcare organization dedicated to serving frail seniors through the Program of All-Inclusive Care for the Elderly (PACE). The company provides a comprehensive model of medical and social care, enabling elderly participants to live healthier, longer, and more independent lives. Founded by experienced physician entrepreneurs, WelbeHealth's leadership team has backgrounds in prominent payer and provider organizations. The company coordinates all aspects of care for its participants, including medical and dental services, therapy, transportation, and meal provision, ensuring a fully integrated approach to health management. By focusing on quality, compassion, and value, WelbeHealth aims to enhance the lives of vulnerable seniors in the community.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. The company utilizes its proprietary Smart Antibody Technology to enhance the success rates of antibody development, significantly expedite the time to market, and lower the associated costs of creating therapeutic antibodies. Adagene is actively engaged in the research, development, and production of monoclonal antibody drugs aimed at treating various types of cancer. Its innovative platform is designed to generate therapeutic antibody candidates that exhibit functional epitopes and species cross-reactivity, underscoring the potential impact of its immunotherapy pipeline in addressing cancer treatment challenges.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, founded in 2016. It specializes in providing primary health care services through an artificial intelligence-based platform that connects patients with healthcare professionals. The company focuses on a virtual-first primary care approach, allowing users to access live video appointments with primary care physicians and care teams. This model emphasizes convenience and accessibility without membership fees, enabling patients to make informed decisions about their health. Firefly Health aims to redefine patient care by blending advanced technology with a dedicated care team to ensure continuous and proactive support for common health conditions, including back pain, stomach flu, and women's health issues.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Protenus, Inc. is a healthcare compliance analytics company based in Baltimore, Maryland, which was founded in 2014. The company specializes in an AI-driven platform designed to audit access to patient records across health systems in the United States. Protenus' technology identifies risks such as inappropriate access to patient data and the misuse of controlled substances by healthcare staff. By automating the detection of policy violations and other anomalous behaviors, the platform supports healthcare organizations in protecting patient privacy and reducing operational risks. Protenus is recognized for its innovation and commitment to fostering safe patient outcomes while enhancing the reputation of healthcare providers. The company has received accolades such as being named one of America's Best Startup Employers by Forbes and recognized as a Great Place to Work.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York City. Founded in 2014, Buoy Health develops an artificial intelligence-driven digital health solution designed to empower individuals in managing their health and navigating the healthcare system. The company's primary offering, Buoy Health, is an online healthcare chatbot that provides personalized symptom analysis, facilitates first-line triage, and offers treatment recommendations. This platform functions as a comprehensive resource, enabling users to engage in self-diagnosis and access information about health benefits. Additionally, Buoy Health can be customized for employers to help employees find in-network providers and access wellness programs, thereby enhancing the overall healthcare experience.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.

Owkin, Inc. is an artificial intelligence company that specializes in developing software aimed at improving treatment outcomes for patients, particularly in oncology. Established in 2016, with headquarters in New York and an office in Paris, Owkin employs AI tools to enhance drug discovery and accelerate clinical trials while safeguarding patient privacy through federated learning. The company offers several products, including Owkin Lab for therapeutic data connection, Owkin Loop for validated and packaged models, and a comprehensive software stack. Owkin's portfolio includes 30 live models, with an additional 40 in development, focusing on identifying new drug candidates and elucidating the mechanisms behind treatment efficacy. Co-founded by Thomas Clozel, a clinical research doctor, and Gilles Wainrib, a machine learning expert, Owkin has raised over $255 million and achieved unicorn status due to its innovative approach in addressing unmet medical needs and optimizing the drug development process.

TreeENT Health is a specialized healthcare provider focused on ear, nose, and throat (ENT) services, established in 2017 and headquartered in Hangzhou, China. The company operates a chain of medical centers that cater to a variety of ENT conditions, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. TreeENT Health utilizes advanced medical technologies, such as minimally invasive surgical techniques, internet-enabled services, and wearable medical devices, to enhance patient care. Their offerings include diagnostic services like Danish ear hearing detection, nasal endoscopy video examinations, and nasopharyngoscopy, along with personalized chronic disease rehabilitation. The integration of online appointment scheduling through platforms like WeChat facilitates convenient access to expert consultations and treatments, ensuring a high-quality experience for patients.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

Avidity Biosciences, Inc. is a biopharmaceutical company based in La Jolla, California, specializing in the development of oligonucleotide-based therapies, particularly through its innovative Antibody Oligonucleotide Conjugates (AOC) platform. This technology aims to address the limitations of traditional oligonucleotide therapies by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide treatments. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disease. In addition to this, the company is advancing multiple programs focused on muscle-related conditions, including muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Furthermore, Avidity is expanding its research to include immune and other cell types, positioning itself at the forefront of biopharmaceutical innovation for serious diseases.

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases characterized by high unmet medical needs. Incorporated in 2016 and based in Oakland, California, the company is known for its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapy specifically targets thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance and increasing mitochondrial DNA copy number, Modis Therapeutics' approach seeks to enhance cellular function and prolong the lives of affected patients. As of September 2019, Modis Therapeutics operates as a subsidiary of Zogenix, Inc.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Notable is an AI-driven platform designed to enhance healthcare operations by automating various workflows. With deployment at over 10,000 care sites, Notable automates more than a million repetitive tasks daily, including Registration and Intake, Scheduling and Referrals, and Authorizations. The platform features a voice-powered application that streamlines physician-patient interactions by structuring conversations, dictations, and orders, while also securely recommending billing codes. This automation not only facilitates personalized and efficient patient care but also alleviates the manual workload for healthcare providers, contributing to their financial health.

WelbeHealth is a healthcare organization dedicated to serving frail seniors through the Program of All-Inclusive Care for the Elderly (PACE). The company provides a comprehensive model of medical and social care, enabling elderly participants to live healthier, longer, and more independent lives. Founded by experienced physician entrepreneurs, WelbeHealth's leadership team has backgrounds in prominent payer and provider organizations. The company coordinates all aspects of care for its participants, including medical and dental services, therapy, transportation, and meal provision, ensuring a fully integrated approach to health management. By focusing on quality, compassion, and value, WelbeHealth aims to enhance the lives of vulnerable seniors in the community.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.